This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

5 Stocks Poised to Pop on Bullish Earnings

Stocks in this article: THRXCRUSAUXLENTROCLR

Theravance

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

My first earnings short-squeeze trade idea this week is biotechnology and drugs player Theravance (THRX), which is set to report results on Tuesday after the market close. This company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections, and central nervous system pain. Wall Street analysts, on average, expect Theravance to report revenue of $1.97 million on a loss of 44 cents per share.

If you're looking for a strong uptrending heavily-shorted biotechnology stock heading into its earnings report this week, then make sure to check out shares of Theravance. This stock has soared over 35% so far in 2012, and it's currently trading just two points off its 52-week high of $31.87 a share.

The current short interest as a percentage of the float for Theravance is extremely high at 16.2%. That means that out of the 47.33 million shares in the tradable float, 9.37 million shares are sold short by the bears. The short-sellers have also been increasing their bets from the last reporting period by 5.6%, or by about 499,000 shares. If Theravance can deliver bullish results, we could see a large short-squeeze develop since the bears are pressing their bets into the quarter.

>>22 Biopharma Stocks With Breakout Potential in 2012

From a technical perspective, THRX is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock triggered a major breakout back in June, when it took out some past overhead resistance at $22.93 to $24.29 a share with massive volume. Since triggering that breakout, shares of THRX have soared to its 52-week high of $31.87 a share. That move has now pushed THRX within range of triggering a near-term breakout trade post-earnings.

If you're bullish on THRX, then I would wait until after earnings and look for long-biased trades if this stock can manage to trigger a break out above some near-term overhead resistance at $30.72 to $31.87 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 599,376 shares. If we get that action, then THRX will enter new 52-week-high territory, and the stock could easily trade north of $35 a share.

I would simply avoid THRX or look for short-biased trades if after earnings it fails to trigger that breakout, and then drops below some major near-term support levels at $29.03 to $28 a share with high volume. If we get that action, then THRX could trend lower toward $25 to $24 a share if the bears hammer this stock down post-earnings.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs